Next Article in Journal
The Pathways of the iRFP713 Unfolding Induced by Different Denaturants
Next Article in Special Issue
Elucidating Functions of FleQ in Xanthomonas oryzae pv. oryzae by Comparative Proteomic and Phenotypic Analyses
Previous Article in Journal
Spatholobus suberectus Ameliorates Diabetes-Induced Renal Damage by Suppressing Advanced Glycation End Products in db/db Mice
Previous Article in Special Issue
Immune Checkpoints as the Immune System Regulators and Potential Biomarkers in HIV-1 Infection
Article Menu
Issue 9 (September) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2018, 19(9), 2775;

Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification

PMI R&D, Philip Morris Products S.A., Quai Jeanrenaud 5, CH-2000 Neuchatel, Switzerland
Lipidomics Consulting Ltd., Irisviksvägen 31D, 02230 Esbo, Finland
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Received: 29 August 2018 / Revised: 11 September 2018 / Accepted: 12 September 2018 / Published: 15 September 2018
(This article belongs to the Collection Advances in Proteomic Research)
PDF [5153 KB, uploaded 15 September 2018]


Inflammatory bowel disease (IBD) represents a group of progressive disorders characterized by recurrent chronic inflammation of the gut. Ulcerative colitis and Crohn′s disease are the major manifestations of IBD. While our understanding of IBD has progressed in recent years, its etiology is far from being fully understood, resulting in suboptimal treatment options. Complementing other biological endpoints, bioanalytical “omics” methods that quantify many biomolecules simultaneously have great potential in the dissection of the complex pathogenesis of IBD. In this review, we focus on the rapidly evolving proteomics and lipidomics technologies and their broad applicability to IBD studies; these range from investigations of immune-regulatory mechanisms and biomarker discovery to studies dissecting host–microbiome interactions and the role of intestinal epithelial cells. Future studies can leverage recent advances, including improved analytical methodologies, additional relevant sample types, and integrative multi-omics analyses. Proteomics and lipidomics could effectively accelerate the development of novel targeted treatments and the discovery of complementary biomarkers, enabling continuous monitoring of the treatment response of individual patients; this may allow further refinement of treatment and, ultimately, facilitate a personalized medicine approach to IBD. View Full-Text
Keywords: inflammatory bowel disease; proteomics; lipidomics; biomarkers; personalized medicine inflammatory bowel disease; proteomics; lipidomics; biomarkers; personalized medicine

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Supplementary material


Share & Cite This Article

MDPI and ACS Style

Titz, B.; Gadaleta, R.M.; Lo Sasso, G.; Elamin, A.; Ekroos, K.; Ivanov, N.V.; Peitsch, M.C.; Hoeng, J. Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification. Int. J. Mol. Sci. 2018, 19, 2775.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top